Although the KRAS mutation, which resulted in EGFR-independent ERK activation, was suggested to be a potential biomarker for predicting the efficacy of EGFR TKI in lung cancer [11], it was rare in HNSCC [12]. The gene discussed is KRAS; the disease is lung carcinoma.